CRNX
Crinetics Pharmaceuticals, Inc.Company Information
- Company Name
- Crinetics Pharmaceuticals, Inc.
- CIK
- CIK0001658247
- Category
- Large accelerated filer
- Ticker: Exchange
- CRNX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CRNX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-07-02
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 231,272
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 114,356,770
- Shares outstanding
- 105,560,000
- Ownership
- 108.33%
Earnings Market Reaction
- Filing date
- 2026-08-03
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 55 | 114 | 102 | 111 | 54 | 95 | 265 | 317 | 302 | 396 | 55 | 143 | ||||||
| Restricted Cash | - | - | 1 | - | - | - | 1 | - | - | - | 0 | - | ||||||
| Restricted Cash Current | - | - | 0 | 1 | 1 | 1 | 1 | - | - | - | - | - | ||||||
| Short Term Investments | 1,150 | 1,177 | 926 | 981 | 1,143 | 1,180 | 1,090 | 545 | 561 | 505 | 504 | 412 | ||||||
| Accounts Receivable Net Current | 12 | 6 | 1 | - | - | - | 0 | - | - | - | - | - | ||||||
| Inventory Net | 3 | 3 | 2 | - | - | - | 0 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 23 | 22 | 18 | 28 | 20 | 16 | 21 | 15 | 12 | 16 | 16 | 21 | ||||||
| Assets Current | 1,244 | 1,322 | 1,048 | 1,121 | 1,217 | 1,291 | 1,375 | 878 | 875 | 917 | 574 | 576 | ||||||
| Property Plant And Equipment Net | 13 | 13 | 14 | 14 | 15 | 13 | 12 | 12 | 12 | 12 | 11 | 10 | ||||||
| Operating Lease Right Of Use Asset | 39 | 40 | 40 | 41 | 42 | 43 | 44 | 44 | 45 | 46 | 47 | 48 | ||||||
| Derivative Assets | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | - | - | - | - | - | 14 | 3 | 3 | 2 | 2 | 2 | 2 | ||||||
| Prepaid Expense And Other Assets Noncurrent | 25 | 25 | 22 | 18 | 15 | - | 3 | - | - | - | - | - | ||||||
| Assets | 1,322 | 1,401 | 1,126 | 1,196 | 1,290 | 1,361 | 1,435 | 937 | 936 | 978 | 635 | 642 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 42 | 37 | 42 | 34 | 38 | 32 | 21 | 18 | 24 | 29 | 23 | 22 | ||||||
| Deferred Revenue Current | - | - | - | - | - | - | - | 2 | 3 | - | - | - | ||||||
| Deferred Revenue | - | - | - | 2 | 2 | 2 | 2 | - | - | 2 | 2 | 2 | ||||||
| Contract With Customer Liability Current | 2 | 1 | 1 | - | - | - | 2 | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 7 | 7 | 6 | 6 | 7 | 7 | 7 | 7 | 7 | 6 | 4 | 4 | ||||||
| Liabilities Current | 80 | 71 | 85 | 74 | 68 | 57 | 60 | 54 | 54 | 52 | 44 | 40 | ||||||
| Operating Lease Liability Noncurrent | 41 | 41 | 42 | 43 | 43 | 44 | 45 | 45 | 46 | 47 | 48 | 48 | ||||||
| Deferred Revenue Noncurrent | - | - | - | 4 | 4 | 4 | 5 | 5 | 4 | 5 | 5 | 5 | ||||||
| Contract With Customer Liability Noncurrent | 3 | 3 | 4 | - | - | - | 5 | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 6 | 5 | 3 | 3 | 2 | 2 | 1 | 1 | 0 | - | 0 | - | ||||||
| Liabilities | 130 | 121 | 134 | 124 | 118 | 107 | 110 | 104 | 105 | 103 | 96 | 94 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stocks Including Additional Paid In Capital | 2,862 | 2,828 | 2,408 | 2,365 | 2,335 | 2,301 | 2,276 | 1,702 | 1,626 | 1,595 | 1,192 | 1,142 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -3 | -1 | 2 | 2 | 2 | 2 | 1 | 2 | -0 | 0 | 1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -1,666 | -1,545 | -1,417 | -1,295 | -1,165 | -1,049 | -952 | -872 | -795 | -721 | -654 | -594 | ||||||
| Common Stock Held In Trust | - | - | - | - | -0 | - | - | - | - | - | - | - | ||||||
| Common Stock Shares Held In Employee Trust | -1 | -1 | -0 | -0 | - | - | 0 | - | - | - | - | - | ||||||
| Stockholders Equity | 1,192 | 1,281 | 992 | 1,072 | 1,172 | 1,254 | 1,325 | 833 | 831 | 875 | 539 | 548 | ||||||
| Liabilities And Stockholders Equity | 1,322 | 1,401 | 1,126 | 1,196 | 1,290 | 1,361 | 1,435 | 937 | 936 | 978 | 635 | 642 | ||||||
| Trading Securities Debt Amortized Cost | 1,153 | 1,178 | 924 | 979 | 1,141 | 1,178 | 1,089 | - | - | - | 503 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 106 | 105 | 96 | 95 | 94 | 94 | 93 | 81 | 79 | 79 | 68 | 67 | ||||||
| Shares Outstanding | 106 | 105 | 96 | 95 | 94 | 94 | 93 | 81 | 79 | 79 | 68 | 32 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCrinetics Pharmaceuticals, Inc. (CRNX) — SEC Financial Statements & Analysis
Crinetics Pharmaceuticals, Inc. (CRNX) is a pharmaceutical preparations company, incorporated in DE. Crinetics Pharmaceuticals, Inc. trades on Nasdaq as: CRNX. Crinetics Pharmaceuticals, Inc. (CRNX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03. Based on that filing, Crinetics Pharmaceuticals, Inc. carries a market cap of $3.95B, a P/E ratio of -7.87x, a P/B ratio of 3.31x, a P/S ratio of 93.70x, an enterprise value of $3.89B, and an EV/EBITDA multiple of -7.15x. On profitability, it posts an operating margin of -1302.52%, a net margin of -1189.88%, a Return on Equity (ROE) of -42.45%, a Return on Assets (ROA) of -38.42%, and a Return on Invested Capital (ROIC) of -48.71%. Per share, it reports EPS of $-4.75, diluted EPS of $-4.75, free cash flow per share of $-4.03, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 2928.45% year-over-year, net income growth of 35.63% year-over-year, and EPS growth of 20.51% year-over-year. On the balance sheet, it maintains a current ratio of 15.57x, a quick ratio of 15.24x, working capital of $1.16B, a debt-to-equity ratio of 0.11x, a debt ratio of 0.1, free cash flow of $-425.18M (TTM), and net debt of $-56.30M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.95B
- P/E TTM
- -7.87x
- EPS TTM
- $-4.75
- P/B TTM
- 3.31x
- ROE TTM
- -42.45%
- ROA TTM
- -38.42%
- Debt To Equity
- 0.11x
- Free Cash Flow TTM
- $-425.18M
- Net Revenue TTM Growth 1Y
- 2928.45%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Crinetics Pharmaceuticals, Inc. in?
Crinetics Pharmaceuticals, Inc. (CRNX) operates in the Pharmaceutical Preparations industry.
What exchange does CRNX trade on?
Crinetics Pharmaceuticals, Inc. (CRNX) trades on the Nasdaq.
Where is Crinetics Pharmaceuticals, Inc. incorporated?
Crinetics Pharmaceuticals, Inc. is incorporated in DE.
When was Crinetics Pharmaceuticals, Inc. (CRNX)'s most recent SEC filing?
Crinetics Pharmaceuticals, Inc. (CRNX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03.
What is CRNX's market cap?
Crinetics Pharmaceuticals, Inc. (CRNX) has a market capitalization of $3.95B as of 2026-06-30.
What is CRNX's EPS (earnings per share)?
Crinetics Pharmaceuticals, Inc. (CRNX)'s trailing twelve month EPS is $-4.75 as of 2026-06-30.
What is CRNX's ROE (return on equity)?
Crinetics Pharmaceuticals, Inc. (CRNX)'s trailing twelve month Return on Equity (ROE) is -42.45% as of 2026-06-30.
What is CRNX's ROA (return on assets)?
Crinetics Pharmaceuticals, Inc. (CRNX)'s trailing twelve month Return on Assets (ROA) is -38.42% as of 2026-06-30.
What is CRNX's ROIC (return on invested capital)?
Crinetics Pharmaceuticals, Inc. (CRNX)'s trailing twelve month Return on Invested Capital (ROIC) is -48.71% as of 2026-06-30.
What is CRNX's EV/EBITDA?
Crinetics Pharmaceuticals, Inc. (CRNX)'s trailing twelve month EV/EBITDA is -7.15x as of 2026-06-30.